EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current management of generalized pustular psoriasis

Nilesh Kodali iD, Isabella Blanchard iD, Sruthi Kunamneni iD, Mark G Lebwohl

Experimental Dermatology · 2023-08 · 32 (8) · 1204-1218

DOI: 10.1111/exd.14765 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Experimental Dermatology, 2023-03. Verfasst von Nilesh Kodali und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Education, Rutgers New Jersey Medical School, Newark, New Jersey, USA. Hauptthemen laut MEDLINE: Psoriasis, Skin Diseases, Vesiculobullous. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Generalized pustular psoriasis (GPP) is a rare subset of psoriasis involving episodes of sterile pustules accompanied by inflammation and, often, systemic involvement. The inflammatory nature of GPP has potential for severe multisystem complications including high‐output cardiac failure, infections, digestive system issues, and disfiguring or lethal acute flare episodes. The disease tends to have higher prevalence in females and Asians. The IL‐1/IL‐36 inflammatory pathway is a critical facet of GPP's pathology. Genetic mutations that are associated with GPP include modifications of Interleukin 36 Receptor Antagonist ( IL36RN ), Caspase Recruitment Domain Family Member 14 ( CARD14 ), Adaptor Related Protein Complex 1 Subunit Sigma 3 ( AP1S3 ), Myeloperoxidase ( MPO ) and Serpin Peptidase Inhibitor Clade A Member 3 ( SERPINA3) genes. Treatment guidelines for GPP are not well‐entrenched. Currently, only one GPP‐specific treatment, the interleukin‐36 receptor antagonist (IL‐36Ra) spesolimab, has been approved for use in the United States. Additional anti‐IL‐36 pathway therapies are currently being developed. Other treatment options include other biologic therapies such as IL‐17 inhibitors, IL‐23 inhibitors and TNFα inhibitors. Non‐biologic therapeutic options include retinoids, cyclosporine and methotrexate. Treatment options differ throughout the world; most countries utilize retinoids, cyclosporine and methotrexate as first‐line non‐biologic options. China and United Kingdom have no GPP‐specific biologic therapies approved for use, while several biologic therapies are approved for use in Japan. This review aims to serve as an update on the current global management of GPP while also including relevant aspects of disease pathogenesis, diagnosis, clinical presentation, histopathology, aetiology and epidemiology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisSkin Diseases, VesiculobullousFemaleHumansInterleukinsMethotrexateCyclosporineAcute DiseaseChronic DiseaseRetinoidsGuanylate CyclaseMembrane ProteinsCARD Signaling Adaptor Proteins

Stichwörter der Autor:innen

GPPIL-36IL-36RNIL-36RaSpesolimabpsoriasissystemic inflammationtreatmentvon Zumbusch

Substanzen

InterleukinsMethotrexateCyclosporineRetinoidsCARD14 protein, humanGuanylate CyclaseMembrane ProteinsCARD Signaling Adaptor ProteinsIL36RN protein, human

Autor:innen und Institutionen

  • Department of Education, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
  • Dermatology, The Icahn School of Medicine at Mount Sinai, New York City, New York, USA.

ORCID-Profile: Nilesh Kodali, Isabella Blanchard, Sruthi Kunamneni

Zitieren

APA

Kodali, N., Blanchard, I., Kunamneni, S., & Lebwohl, M. G. (2023). Current management of generalized pustular psoriasis. Experimental Dermatology, 32(8), 1204-1218. https://doi.org/10.1111/exd.14765

Vancouver

Kodali N, Blanchard I, Kunamneni S, Lebwohl MG. Current management of generalized pustular psoriasis. Experimental Dermatology. 2023;32(8):1204-1218. doi:10.1111/exd.14765

BibTeX
@article{Kodali2023,
  author = {Kodali, Nilesh and Blanchard, Isabella and Kunamneni, Sruthi and Lebwohl, Mark G},
  title = {Current management of generalized pustular psoriasis},
  journal = {Experimental Dermatology},
  year = {2023},
  volume = {32},
  number = {8},
  pages = {1204--1218},
  doi = {10.1111/exd.14765}
}
Kostenlos starten →